clinical trial · NCT05794581
A Study to Assess the Effects of CT-868 Treatment on Glucose Homeostasis in Participants with Type 1 Diabetes
Carmot Therapeutics, Inc.·phase1·completed·n = 32
Type 1 DiabetesCT-868PlaceboVictoza
brief summary
This study will be conducted primarily to evaluate the effects of CT-868 on glucose homeostasis in participants with Type 1 Diabetes Mellitus.
started
Mar 21, 2023
primary completion
Mar 6, 2024
completion
Apr 6, 2024
last updated
Dec 27, 2024
official title
A Randomized, Double-Blind, Placebo and Comparator-Controlled Crossover Study to Assess the Effects of CT-868 Treatment on Glucose Homeostasis in Participants with Type 1 Diabetes
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol